echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Glycine in tumors is used as a marker for MRS detection of gliomas

    Glycine in tumors is used as a marker for MRS detection of gliomas

    • Last Update: 2021-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Magnetic resonance spectrometry (MRS) is a non-invasive biomarker imaging method, which is widely used to detect the mutation status of brain tumor, diagnosis of glioma and evaluation of tumor invasiveness by analyzing tumor-specific metabolic processes in the body.
    Vivek Tiwari of the Center for Advanced Imaging Research at the University of Texas Southwestern Medical Center and others used MRS to detect glycine levels in patients with glioma and to analyze the correlation between tumor progression and clinical prognosis.
    results were published in Neuro-Oncology in July 2020.
    high-level gliomas meet the nutritional needs of rapid cell proliferation by reshaping metabolic mechanisms.
    glycine as an intermediate product of nucleotide biosynthetics, the content increases with cell proliferation.
    researchers used MRS to detect glycine, 2-hydroxypropypyt acid (2HG) and other tumor-related metabolites in 35 glioma patients; Levels of glycine and 2HG expression in prosurromas (Figure 1), tumor proliferation and progression increased when glycine content increased (Figure 2), and high glycine/2HG ratios indicated poor survival prognosis in patients (Figure 3).
    35 patients with glioma showed levels of glycine and 2HG expression.
    2. The relationship between the expression of glycine and 2HG and tumor progression.
    Figure 3. Kaplan-Meier analyzes the effects of metabolites and enzyme expression levels on the overall survival of patients.
    conclusion The authors conclude that MRS, as a non-invasive secondary testing tool, can predict tumor progression and clinical prognosticity by detecting glycine content.
    : The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
    , editing, copying, cutting, recording, etc. without permission.
    be used with a license, the source must also be indicated.
    welcome to forward and share.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.